Prognostic impact of angiotensin-converting enzyme inhibitors and angiotensin receptors blockers in cancer patients
Not Applicable
- Conditions
- Cancer Patients
- Registration Number
- JPRN-UMIN000052284
- Lead Sponsor
- Yokohama City University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Systematic review or meta-analysis articles. (2) Retrospective analysis. (3) Single prospective cohort study without a control group. (4) Non-RCT. (5) The republished research literature is excluded unless the research includes new findings related to outcomes listed in inclusion criteria. (6) Studies with no or insufficient safety results at the time of the literature search. (7) Studies published in languages other than English. Two investigators independently screened all titles, abstracts, and full texts for eligibility. Final inclusion will be decided after resolving discrepancies between the two investigators.
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint is to evaluate ACE inhibitor/ARB treatment in patients being treated for malignancy in relation to reduction in cardiotoxicity, respiratory distress, and improvement in quality of life.
- Secondary Outcome Measures
Name Time Method